From CVS to Google, here are 20 healthcare executives to watch VC firms, biotechs push back on drug pricing bill that would render small molecule drugs 'uninvestable' Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts slashes its Eylea sales estimate Philips predicts sleep machine sales to recover by 2025 as ventilator recall rages on What Amazon's $4B One Medical play reveals about its healthcare ambitions Verily’s heart-tracking wearable evolves into the Zio Watch via iRhythm partnership, new FDA clearances Bavarian Nordic wins monkeypox vaccine approval in Europe as WHO declares a global emergency Pfizer, BMS vet hits Replay with $55M seed financing, 'Big DNA' ambitions Beyond skin supplements: collagen could be the next target for cancer therapies US manufacturing group runs 6-figure ad campaign lambasting Congress' latest drug pricing bill CBO: Extending enhanced ACA subsidies permanently may net 4.8M increase in sign-ups each year As COVID market narrows, SaNOtize moves to carve a new one: over-the-counter prevention Cleerly quadruples previous funding with $192M for heart attack-predicting AI Featured Story | By Anastassia Gliadkovskaya,Robert King,Susan Kreimer,Heather Landi,Paige Minemyer,Dave Muoio,Jacqueline Renfrow Healthcare is complicated, and few people know that better than the executives leading the industry. Meet the 20 we're highlighting here, and let us know on Twitter at @FierceHealth the executives you're watching. read more |
| |
|---|
|
Top Stories By Annalee Armstrong Some of the leading biotech investment firms say the senate’s proposed drug pricing bill will render the pursuit of small molecule drugs “uninvestable,” especially new therapies for diseases of aging, including Alzheimer’s disease, blindness, amyotrophic lateral sclerosis and more. read more By Kevin Dunleavy Doubts about the ability of Regeneron to succeed in phase 3 trials of its high-dose version of Eylea and growing confidence in Roche’s newly-approved challenger Vabysmo have led analysts at SVB Leerink to slash their 2027 U.S. sales estimates for the macular degeneration blockbuster from $4.6 billion to $3.4 billion. read more By Andrea Park While declines in recent quarters have primarily been attributed to its vast ventilator recall effort and ongoing supply chain issues, this time around Philips linked its sales slump in large part to COVID-19 lockdowns in China. read more By Heather Landi As Amazon has built its business with a laser focus on the consumer, the company's bigger push into healthcare raises the stakes for other players to take a consumer-centric approach, industry experts say. Businesses like Amazon with a national customer base have a unique opportunity to expand their share of wallet with loyal customers. read more By Conor Hale It's been a long journey, but iRhythm’s long-running partnership with Google’s life science-focused sister company Verily has finally reached its destination: The FDA handed down its blessing for the pair’s smartwatch and software used to detect atrial fibrillation. read more By Zoey Becker As the monkeypox outbreak presses on, the World Health Organization has declared the disease a public health emergency. Meanwhile, the EU granted the company's vaccine an approval to prevent monkeypox. read more By Gabrielle Masson New biotech Replay—led by former Pfizer and Bristol Myers Squibb executive Adrian Woolfson, Ph.D.—has unveiled with a $55 million seed financing to reprogram biology and author next generation genomic products. read more By James Waldron Collagen supplements may be a regular fixture on the shelves of your local vitamin shop, but researchers at the University of Texas have suggested that this most abundant protein in the body may have a new use: to fight cancer. read more By Ben Adams The National Association of Manufacturers is spending some serious bucks to try and stop a sweeping proposal in the Senate to control drug pricing in the U.S. read more By Robert King The Congressional Budget Office projected permanently extending enhanced ACA subsidies would lead to an increase of nearly 5 million sign-ups a year. read more By Max Bayer There are currently zero authorized or approved preventative COVID therapies in the U.S. but Canadian biotech SaNOtize wants to change that, charting plans to move a nasal spray into a phase 3 study as soon as October. read more By Andrea Park After proving that its noninvasive artificial intelligence software is comparable to the current gold standard of coronary angiography in spotting signs of heart disease, Cleerly has cleared a path to bring the technology to even more people around the world. read more Resources Sponsored by: NetApp Could cloud be the cure for your EHR headaches? See our infographic on how moving to the cloud can slash financial and administrative burdens. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 